Company Overview


Our name is inspired by science. It is an abstraction of the word ‘science’ + ‘zygote’ (the fusion of two cells), representing the beginning of life. Our name also embeds ‘us’ as a reference to our teamwork, partnerships and our commitment to the broader ‘us’ -society.

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of phyto-therapeutics, including cannabinoid and protein-based formulations. Our strategy is to focus exclusively on patients by delivering high-quality, consistent and GMP-compliant therapeutic products to the global medical market.

Our aim is to shift the paradigm from the treatment of physical disease to caring for overall well-being, by accelerating the adoption of phyto-therapeutics. We use science as a driver to establish phyto-therapeutics as a standard of care for treating disease and managing the experience of it. To achieve this, we are investing in:

  • Upstream molecular biology
  • Traditional plant breeding
  • Molecule purification optimization
  • Pre-clinical model testing
  • Clinical trials
  • Advancing process manufacturing
  • Defining scientific standards
  • High-quality offerings
  • Raising awareness of medical needs

ZYUS was founded by Brent Zettl, the former President and CEO of CanniMed Therapeutics Inc. and other senior members of his management team. Brent and his team were the first and exclusive supplier of medical cannabis to Health Canada from 2000 to 2014. With decades of experience pioneering the medical cannabis industry, ZYUS has set a vision to elevate cannabinoids as a standard of care and reimagine the potential of medicine in pursuit of a transformational impact on patients’ lives.

ZYUS. Advancing the science of well-being.